Business
Arbor Biotechnologies Appoints Mikael Dolsten, M.D., Ph.D., to Board of Directors
Former Pfizer Chief Scientific Officer brings decades of drug development and strategic leadership experience to Arbor’s BoardCAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Arbor Biotechnologies™, a biotechnology company discovering and developing the next generation of genetic medicines, today announced the appointment of Mikael Dolsten, M.D., Ph.D., to its Board of Directors. Dr. Dolsten most recently served as Chief Scientific Officer and President of Worldwide Research, Development, and
About this update from Arbor Realty Trust
[{"type":"image","alt":"Arbor Biotechnologies Inc","displaySize":"","headline":null,"caption":"Arbor Biotechnologies Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":221,"url":"https://media.zenfs.com/en/globenewswire.com/4b02fcaab8948ff6e6bc489a844735a6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/i.0i7dM_GfTQZaHQoFq6hQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMwOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/4b02fcaab8948ff6e6bc489a844735a6","width":300,"height":221}},"lazy":false},{"type":"text","content":"Former Pfizer Chief Scientific Officer brings decades of drug development and strategic leadership experience to Arbor’s Board","length":126,"tagName":"p"},{"type":"text","content":"CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Arbor Biotechnologies™, a biotechnology company discovering and developing the next generation of genetic medicines, today announced the appointment of Mikael Dolsten, M.D., Ph.D., to its Board of Directors. Dr. Dolsten most recently served as Chief Scientific Officer and President of Worldwide Research, Development, and Medical at Pfizer Inc., where he led R&D strategy and portfolio advancement for more than 16 years.","length":478,"tagName":"p"},{"type":"text","content":"“Mikael’s experience leading world-class R&D organizations and guiding companies through periods of scientific and operational inflection will be a tremendous asset to Arbor,” said Paul Meister, Chairman of the Board of Arbor Biotechnologies. “We are excited to welcome him and look forward to his insights as the company progresses the development of its differentiated portfolio of gene editing therapeutics.” ","length":446,"tagName":"p"},{"type":"text","content":"A physician-scientist and biopharma leader, Dr. Dolsten played a central role in developing and advancing breakthrough innovations across small molecules, biologics, gene therapies, and vaccines—including leading the company’s scientific response to the COVID-19 pandemic. His leadership has shaped portfolios at several global pharmaceutical companies, including Boehringer Ingelheim, AstraZeneca, and Wyeth, and he has contributed to corporate transactions exceeding $100 billion in value.","length":491,"tagName":"p"},{"type":"text","content":"“I am thrilled to join Arbor’s Board and support the team in re...